drugset / Trial / NCT00101634

Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia

NCT00101634

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.

Timeline

Start
2004-12
Primary completion
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject paliperidone palmitate Unknown 25 mg Intramuscular
Subject paliperidone palmitate Unknown 50 mg Intramuscular
Subject paliperidone palmitate Unknown 100 mg Intramuscular

Indications